The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A pharmacokinetic (PK) and pharmacodynamic (PD) biomarker-driven phase I study of intermittent, low dose intensity schedules of the dual MEK/RAF inhibitor, RO5126766 (RO) in patients (pts) with advanced solid tumors.
 
Maria Jose de Miguel Luken
No Relationships to Disclose
 
Desamparados Roda
No Relationships to Disclose
 
Raquel Perez Lopez
No Relationships to Disclose
 
Begona Jimenez
No Relationships to Disclose
 
Hasina Hassam
No Relationships to Disclose
 
Nitharsan Sathiyayogan
No Relationships to Disclose
 
Mona Parmar
No Relationships to Disclose
 
Alison Joanne Turner
No Relationships to Disclose
 
Emma Hall
No Relationships to Disclose
 
Nina Tunariu
No Relationships to Disclose
 
L Rhoda Molife
No Relationships to Disclose
 
Timothy Anthony Yap
No Relationships to Disclose
 
Johann Sebastian De Bono
Honoraria - Astellas Pharma; AstraZeneca; Genentech/Roche; Pfizer; Sanofi
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Genentech/Roche; Sanofi
Research Funding - Arno Therapeutics (Inst); AstraZeneca (Inst); Genentech (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
 
Udai Banerji
Honoraria - Astex Pharmaceuticals
Consulting or Advisory Role - Astex Pharmaceuticals
Research Funding - AstraZeneca; Chugai Pharma; Lupin Pharmaceuticals; Merck; Novartis; Onyx; Synthon; Verastem